The Technical Analyst
Cannabics Pharmaceuticals [CNBX]
Exchange: PNK Industry: Biotechnology
Cannabics Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0114
America/New_York / 3 mai 2024 @ 15:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.355 mill |
| EPS: | 0.980 |
| P/E: | 0.0100 |
| Earnings Date: | Jul 14, 2024 |
| SharesOutstanding: | 31.11 mill |
| Avg Daily Volume: | 0.233 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.0100 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 0.0100 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0084 - 0.0144 ( +/- 26.32%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2014-07-25 | Cannabics Inc. | Buy | 18 239 594 | COMMON STOCK |
| 2014-06-23 | Cannabics Inc. | Buy | 14 525 000 | Common Stock |
| 2014-05-08 | Cannabics Inc. | Buy | 20 500 000 | Common Stock |
| 2014-05-08 | Mills Thomas E | Sell | 20 500 000 | common stock |
| 2014-04-25 | Mills Thomas E | Buy | 20 500 000 | common stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 15 transactions |
| Buy: 135 764 594 | Sell: 73 500 000 |
Forecast:
16:00 - $0.0114
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0114
Forecast 2: 16:00 - $0.0114
Forecast 3: 16:00 - $0.0114
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0114 (0.00% ) |
| Volume | 0.140 mill |
| Avg. Vol. | 0.233 mill |
| % of Avg. Vol | 59.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CNBX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CNBX
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Latest Press Releases
2021-10-19 09:41:00 - Press Release
Ceo Of Cannabics Pharmaceuticals, Eyal Barad, To Present At Edison Open Forum: Cannabinoids 2021
Tel aviv, israel and bethesda, md., oct. 19, 2021 /prnewswire/ -- cannabics pharmaceuticals inc. (otc: cnbx), a global leader in the development of cancer related cannabinoid-based medicine, announced today that company ceo, eyal barad, will present at the upcoming edison open forum: cannabinoids 2021, taking place today, wednesday, october 19 th.
2021-10-18 09:05:00 - Press Release
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions And Methods For Treating Cancer
Tel aviv, israel and bethesda, md., oct. 18, 2021 /prnewswire/ -- cannabics pharmaceuticals inc. (otc: cnbx), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new provisional patent applications on compositions and methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
2021-09-30 09:25:00 - Press Release
Cannabics Announces New Corporate Logo, New Website And New Company Presentation
Tel aviv, israel and bethesda, md., sept. 30, 2021 /prnewswire/ -- cannabics pharmaceuticals inc. (otcqb: cnbx), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website.
2021-09-22 09:15:00 - Press Release
Gabriel Yariv, Executive Director Of Cannabics Pharmaceuticals And Dr. David Sans Will Participate At The Icdp Summit In Boston
Tel aviv, israel and bethesda, md., sept. 22, 2021 /prnewswire/ -- cannabics pharmaceuticals inc. (otcqb: cnbx), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the company will present at the 4th annual international cannabinoid-derived pharmaceuticals summit in boston.
2021-09-21 09:20:00 - Press Release
Cannabics Pharmaceuticals Hires Healthcare Investment Banker Dr. David Sans In New York To Expand Cnbx In Mental Health Diseases
Tel aviv, israel and bethesda, maryland, sept. 21, 2021 /prnewswire/ -- cannabics pharmaceuticals inc. (cnbx), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of dr. david sans faarm, phd, mba in new york to expand its current pipeline of clinical development assets in mental health diseases.
Latest News
2021-10-19 09:41:00 - PRNewsWire
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19 th.
2021-10-18 12:49:41 - Benzinga
Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients. These patent applications are now part of the Cannabics growing IP portfolio comprising of eight patent families with five granted patents and 19 pending applications.
2021-10-18 09:05:00 - PRNewsWire
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
2021-09-30 09:25:00 - PRNewsWire
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website.
2021-09-22 09:15:00 - PRNewsWire
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.
2021-09-21 09:20:00 - PRNewsWire
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.
2021-09-13 08:25:00 - PRNewsWire
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.
2021-08-04 08:00:00 - PRNewsWire
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD.
2021-07-20 07:35:00 - PRNewsWire
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board.
2021-07-07 08:50:00 - PRNewsWire
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.